丁型肝炎病毒研究进展
|
摘要
丁型肝炎病毒(HDV)是乙型肝炎病毒(HBV)的卫星病毒,呈世界性流行,其感染和复制与HBV感染存在密不可分的联系。我国是HBV感染的高发国家之一,HBV相关研究较多,但对其卫星病毒HDV的研究较少。我们较全面地梳理了HDV的分子生物学特征、流行病学特点、实验研究模型、检测、预防及治疗几个方面的最新进展,期望对未来HDV的研究起到一定的推动作用。
Hepatitis D virus(HDV), the satellite of hepatitis B virus(HBV), is a worldwide human pathogen.The infection and replication of HDV are inseparable with HBV. China is one of the countries with high incidence of HBV infection, and many research projects focus on HBV but few on its satellite virus HDV. In this review, the latest developments in HDV molecular biology, epidemiological characteristics, experimental models, detection, prevention and treatment were introduced and summarized comprehensively. We hope this paper can play a certain role in the future study of HDV.
Hepatitis D virus(HDV), the satellite of hepatitis B virus(HBV), is a worldwide human pathogen.The infection and replication of HDV are inseparable with HBV. China is one of the countries with high incidence of HBV infection, and many research projects focus on HBV but few on its satellite virus HDV. In this review, the latest developments in HDV molecular biology, epidemiological characteristics, experimental models, detection, prevention and treatment were introduced and summarized comprehensively. We hope this paper can play a certain role in the future study of HDV.
引文
[1]Price J.An update on hepatitis B,D,and E viruses[J].Top Antivir Med,2014,21(5):157-163.
[2]Shen L P,Gu Y,Sun L,et al.Development of a hepatitis delta virus antibody assay for study of the prevalence of HDV among individuals infected with hepatitis B virus in China[J].Med Virol,2012,84:445-449.
[3]Cunha C,Tavanez J P,Gudima S.Hepatitis delta virus:a fascinating and neglected pathogen[J].World J Virol,2015,4(4):313-322.
[4]Taylor J M.Host RNA circles and the origin of hepatitis delta virus[J].World J Gastroenterol,2014,20(11):2971-2978.
[5]Hughes S A,Wedemeyer H,Harrison P M.Hepatitis delta virus[J].Lancet,2011,378(9785):73-85.
[6]Kao J H,Chen P J,Lai M Y,et al.Hepatitis D virus genotypes in intravenous drug users in Taiwan:decreasing prevalence and lack of correlation with hepatitis B virus genotypes[J].J Clin Microbiol,2002,40(8):3047-3049.
[7]Sharmeen L,Kuo M Y,Dinter-Gottlieb G,et al.The antigenomic RNA of human hepatitis delta virus can undergo selfcleavage[J].J Virol,1988,62(8):2674-2679.
[8]Alvarado-Mora M V,Locarnini S,Rizzetto M.An update on HDV:virology,pathogenesis and treatment[J].Antivir Ther,2013,18(3 Pt B):541-548.
[9]Taylor J M.Hepatitis D virus replication[J].Cold Spring Harb Perspect Med,2015,5(11):a021568.
[10]Alfaiate D,Dény P,Durantel D.Hepatitis delta virus:from biological and medical aspects to current and investigational therapeutic options[J].Antiviral Res,2015,122:112-29.
[11]卢学新,伊瑶,毕胜利.丁型肝炎的分子生物学特征及研究进展[J].中华实验和临床病毒学杂志,2013,27(3):236-238.
[12]Kao J H,Chen P J,Lai M Y,et al.Hepatitis D virus genotypes in intravenous drug users in Taiwan:decreasing prevalence and lack of correlation with hepatitis B virus genotypes[J].J Clin Microbiol,2002,40:3047-3049.
[13]Pascarella S,Negro F.Hepatitis D virus:an update[J].Liver Int,2011,31(1):7-21.
[14]Rizzetto M,Ciancio A.Epidemiology of hepatitis D[J].Semin Liver,2012,32(3):211-219.
[15]吴志德,周沛林.丁型肝炎病毒感染标志物在乙型肝炎病毒感染者中的检测研究[J].中华医院感染学杂志,2013,23(13):3294-3295.
[16]许泼实,韩双印,孙长义,等.乙型肝炎病毒感染者血清中丁型肝炎病毒标志物检测分析[J].中华实验和临床病毒学杂志,2012,26(4):307-309.
[17]Shen L,Gu Y,Sun L,et al.Development of a hepatitis delta virus antibody assay for study of the prevalence of HDV among individuals infected with hepatitis B virus in China[J].J Med Virol,2012,84(3):445-449.
[18]杨松,邢卉春,成军.慢性丁型肝炎抗病毒治疗进展[J/CD].中华实验和临床感染病杂志,2011,5(4):484-488.
[19]Ni Y,Lempp F A,Mehrle S,et al.Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes[J].Gastroenterology,2014,146:1070-1083.
[20]Yan H,Zhong G,Xu G,et al.Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus[J].Elife(Cambridge),2012,1:e00049.
[21]Wang X J,Hu W,Zhang T Y,et al.Irbesartan,an FDA approved drug for hypertension and diabetic nephropathy,is a potent inhibitor for hepatitis B virus entry by disturbing Na(+)-dependent taurocholate cotransporting polypeptide activity[J].Antiviral Res,2015,120:140-146.
[22]Guidotti L G,Rochford R,Chung J,et al.Viral clearance without destruction of infected cells during acute HBV infection[J].Science,1999,284(5415):825-829.
[23]Casey J L,Gerin J L.The woodchuck model of HDV infection[J].Curr Top Microbiol Immunol,2006,307:211-225.
[24]Netter H J,Kajino K,Taylor J M.Experimental transmission of human hepatitis delta virus to the laboratory mouse[J].J Virol,1993,67(6):3357-3362.
[25]Chang J,Sigal L J,Lerro A,et al.Replication of the human hepatitis delta virus genome Is initiated in mouse hepatocytes following intravenous injection of naked DNA or RNA sequences[J].J Virol,2001,75(7):3469-3473.
[26]He W,Ren B,Mao F,et al.Hepatitis D virus infection of mice expressing human sodium taurocholate cotransporting polypeptide[J].PLo S Pathog,2015,11(4):e1004840.
[27]邵惠训.一种缺陷病毒——丁型肝炎病毒[J].首都公共卫生,2011,5(3):115-119.
[28]Wranke A,Heidrich B,Ernst S,et al.Anti-HDV Ig M as a marker of disease activity in hepatitis delta[J].PLo S One,2014,9(7):e101002.
[29]Romeo R,Foglieni B,Casazza G,et al.High serum levels of HDV RNA are predictors of cirrhosis and liver cancer in patients with chronic hepatitis delta[J].PLo S One,2014,9(3):e92062.
[30]Romeo R,Foglieni B,Casazza G,et al.High serum levels of HDV RNA are predictors of cirrhosis and liver cancer in patients with chronic hepatitis delta[J].PLo S One,2014,9(3):e92062.
[31]Botelho-Souza L F,dos Santos Ade O,Borzacov L M,et al.Development of a reverse transcription quantitative real-time PCR-based system for rapid detection and quantitation of hepatitis delta virus in the western Amazon region of Brazil[J].J Virol Methods,2014,197:19-24.
[32]Le Gal F,Brichler S,Sahli R,et al.First international external quality assessment for hepatitis delta virus RNA quantification in plasma[J].Hepatology,2016,64(5):1483-1494.
[33]郑猛.病毒性肝炎的预防及其疫苗应用[J].世界最新医学信息文摘,2016,16(30):295-296.
[34]European association for the study of the liver.EASL clinical practice guidelines:management of chronic hepatitis B virus infection[J].Hepatology,2012,57:167-185.
[35]Visco-Comandini U,Lapa D,Taibi C,et al.No impact of interleukin-28B polymorphisms on spontaneous or drug-induced hepatitis delta virus clearance[J].Dig Liver Dis,2014,46(4):348-352.
[36]Yilmaz E,Baran B,Soyer O M,et al.Effects of polymorphisms in interferonλ3(interleukin 28B)on sustained virologic response to therapy in patients with chronic hepatitis D virus infection[J].Clin Gastroenterol Hepatol,2014,12(10):1753-1758.
[37]Abeywickrama-Samarakoon N,Cortay J C,Dény P.The hepatitis D satellite virus of hepatitis B virus:half-opening a new era to control viral infection[J]?Curr Opin Infect Dis,2016,29(6):645-653.
[38]Niro G A,Ciancio A,Tillman H L,et al.Lamivudine therapy in chronic delta hepatitis:a multicentre randomized-controlled pilot study[J].Aliment Pharmacol Ther,2005,22(3):227-232.
[39]Wedemeyer H,Yurdaydìn C,Dalekos G N,et al.Peginterferon plus adefovir versus either drug alone for hepatitis delta[J].N Engl J Med,2011,364(4):322-331.
[40]Kaba?am G,Onder F O,Yakut M,et al.Entecavir treatment of chronic hepatitis D[J].Clin Infect Dis,2012,55(5):645-650.
[41]Rizzetto M.Hepatitis D:thirty years after[J].J Hepatol,2009,50(5):1043-1050.
[42]Chang J,Taylor J M.Susceptibility of human hepatitis delta virus RNAs to small interfering RNA action[J].J Virol,2003,77(17):9728-9731.
[43]Singh S,Gupta S K,Nischal A,et al.Design of potential si RNA molecules for hepatitis delta virus gene silencing[J].Bioinformation,2012,8(16):749-757.
[44]何庆军.分析病毒性肝炎的中医治疗[J].中医临床研究,2014,17(6):107.
[45]王融冰.肝病的中医药治疗[J].临床肝胆病杂志,2015,31(1):2-6.
[2]Shen L P,Gu Y,Sun L,et al.Development of a hepatitis delta virus antibody assay for study of the prevalence of HDV among individuals infected with hepatitis B virus in China[J].Med Virol,2012,84:445-449.
[3]Cunha C,Tavanez J P,Gudima S.Hepatitis delta virus:a fascinating and neglected pathogen[J].World J Virol,2015,4(4):313-322.
[4]Taylor J M.Host RNA circles and the origin of hepatitis delta virus[J].World J Gastroenterol,2014,20(11):2971-2978.
[5]Hughes S A,Wedemeyer H,Harrison P M.Hepatitis delta virus[J].Lancet,2011,378(9785):73-85.
[6]Kao J H,Chen P J,Lai M Y,et al.Hepatitis D virus genotypes in intravenous drug users in Taiwan:decreasing prevalence and lack of correlation with hepatitis B virus genotypes[J].J Clin Microbiol,2002,40(8):3047-3049.
[7]Sharmeen L,Kuo M Y,Dinter-Gottlieb G,et al.The antigenomic RNA of human hepatitis delta virus can undergo selfcleavage[J].J Virol,1988,62(8):2674-2679.
[8]Alvarado-Mora M V,Locarnini S,Rizzetto M.An update on HDV:virology,pathogenesis and treatment[J].Antivir Ther,2013,18(3 Pt B):541-548.
[9]Taylor J M.Hepatitis D virus replication[J].Cold Spring Harb Perspect Med,2015,5(11):a021568.
[10]Alfaiate D,Dény P,Durantel D.Hepatitis delta virus:from biological and medical aspects to current and investigational therapeutic options[J].Antiviral Res,2015,122:112-29.
[11]卢学新,伊瑶,毕胜利.丁型肝炎的分子生物学特征及研究进展[J].中华实验和临床病毒学杂志,2013,27(3):236-238.
[12]Kao J H,Chen P J,Lai M Y,et al.Hepatitis D virus genotypes in intravenous drug users in Taiwan:decreasing prevalence and lack of correlation with hepatitis B virus genotypes[J].J Clin Microbiol,2002,40:3047-3049.
[13]Pascarella S,Negro F.Hepatitis D virus:an update[J].Liver Int,2011,31(1):7-21.
[14]Rizzetto M,Ciancio A.Epidemiology of hepatitis D[J].Semin Liver,2012,32(3):211-219.
[15]吴志德,周沛林.丁型肝炎病毒感染标志物在乙型肝炎病毒感染者中的检测研究[J].中华医院感染学杂志,2013,23(13):3294-3295.
[16]许泼实,韩双印,孙长义,等.乙型肝炎病毒感染者血清中丁型肝炎病毒标志物检测分析[J].中华实验和临床病毒学杂志,2012,26(4):307-309.
[17]Shen L,Gu Y,Sun L,et al.Development of a hepatitis delta virus antibody assay for study of the prevalence of HDV among individuals infected with hepatitis B virus in China[J].J Med Virol,2012,84(3):445-449.
[18]杨松,邢卉春,成军.慢性丁型肝炎抗病毒治疗进展[J/CD].中华实验和临床感染病杂志,2011,5(4):484-488.
[19]Ni Y,Lempp F A,Mehrle S,et al.Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes[J].Gastroenterology,2014,146:1070-1083.
[20]Yan H,Zhong G,Xu G,et al.Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus[J].Elife(Cambridge),2012,1:e00049.
[21]Wang X J,Hu W,Zhang T Y,et al.Irbesartan,an FDA approved drug for hypertension and diabetic nephropathy,is a potent inhibitor for hepatitis B virus entry by disturbing Na(+)-dependent taurocholate cotransporting polypeptide activity[J].Antiviral Res,2015,120:140-146.
[22]Guidotti L G,Rochford R,Chung J,et al.Viral clearance without destruction of infected cells during acute HBV infection[J].Science,1999,284(5415):825-829.
[23]Casey J L,Gerin J L.The woodchuck model of HDV infection[J].Curr Top Microbiol Immunol,2006,307:211-225.
[24]Netter H J,Kajino K,Taylor J M.Experimental transmission of human hepatitis delta virus to the laboratory mouse[J].J Virol,1993,67(6):3357-3362.
[25]Chang J,Sigal L J,Lerro A,et al.Replication of the human hepatitis delta virus genome Is initiated in mouse hepatocytes following intravenous injection of naked DNA or RNA sequences[J].J Virol,2001,75(7):3469-3473.
[26]He W,Ren B,Mao F,et al.Hepatitis D virus infection of mice expressing human sodium taurocholate cotransporting polypeptide[J].PLo S Pathog,2015,11(4):e1004840.
[27]邵惠训.一种缺陷病毒——丁型肝炎病毒[J].首都公共卫生,2011,5(3):115-119.
[28]Wranke A,Heidrich B,Ernst S,et al.Anti-HDV Ig M as a marker of disease activity in hepatitis delta[J].PLo S One,2014,9(7):e101002.
[29]Romeo R,Foglieni B,Casazza G,et al.High serum levels of HDV RNA are predictors of cirrhosis and liver cancer in patients with chronic hepatitis delta[J].PLo S One,2014,9(3):e92062.
[30]Romeo R,Foglieni B,Casazza G,et al.High serum levels of HDV RNA are predictors of cirrhosis and liver cancer in patients with chronic hepatitis delta[J].PLo S One,2014,9(3):e92062.
[31]Botelho-Souza L F,dos Santos Ade O,Borzacov L M,et al.Development of a reverse transcription quantitative real-time PCR-based system for rapid detection and quantitation of hepatitis delta virus in the western Amazon region of Brazil[J].J Virol Methods,2014,197:19-24.
[32]Le Gal F,Brichler S,Sahli R,et al.First international external quality assessment for hepatitis delta virus RNA quantification in plasma[J].Hepatology,2016,64(5):1483-1494.
[33]郑猛.病毒性肝炎的预防及其疫苗应用[J].世界最新医学信息文摘,2016,16(30):295-296.
[34]European association for the study of the liver.EASL clinical practice guidelines:management of chronic hepatitis B virus infection[J].Hepatology,2012,57:167-185.
[35]Visco-Comandini U,Lapa D,Taibi C,et al.No impact of interleukin-28B polymorphisms on spontaneous or drug-induced hepatitis delta virus clearance[J].Dig Liver Dis,2014,46(4):348-352.
[36]Yilmaz E,Baran B,Soyer O M,et al.Effects of polymorphisms in interferonλ3(interleukin 28B)on sustained virologic response to therapy in patients with chronic hepatitis D virus infection[J].Clin Gastroenterol Hepatol,2014,12(10):1753-1758.
[37]Abeywickrama-Samarakoon N,Cortay J C,Dény P.The hepatitis D satellite virus of hepatitis B virus:half-opening a new era to control viral infection[J]?Curr Opin Infect Dis,2016,29(6):645-653.
[38]Niro G A,Ciancio A,Tillman H L,et al.Lamivudine therapy in chronic delta hepatitis:a multicentre randomized-controlled pilot study[J].Aliment Pharmacol Ther,2005,22(3):227-232.
[39]Wedemeyer H,Yurdaydìn C,Dalekos G N,et al.Peginterferon plus adefovir versus either drug alone for hepatitis delta[J].N Engl J Med,2011,364(4):322-331.
[40]Kaba?am G,Onder F O,Yakut M,et al.Entecavir treatment of chronic hepatitis D[J].Clin Infect Dis,2012,55(5):645-650.
[41]Rizzetto M.Hepatitis D:thirty years after[J].J Hepatol,2009,50(5):1043-1050.
[42]Chang J,Taylor J M.Susceptibility of human hepatitis delta virus RNAs to small interfering RNA action[J].J Virol,2003,77(17):9728-9731.
[43]Singh S,Gupta S K,Nischal A,et al.Design of potential si RNA molecules for hepatitis delta virus gene silencing[J].Bioinformation,2012,8(16):749-757.
[44]何庆军.分析病毒性肝炎的中医治疗[J].中医临床研究,2014,17(6):107.
[45]王融冰.肝病的中医药治疗[J].临床肝胆病杂志,2015,31(1):2-6.